Novavax
Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine
- Conditions
- Respiratory Syncytial Virus Infections
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2012-03-08
- Lead Sponsor
- Novavax
- Target Recruit Count
- 150
- Registration Number
- NCT01290419
- Locations
- 🇺🇸
Healthcare Discoveries d/b/a ICON Development Solutions, San Antonio, Texas, United States
Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine
- Conditions
- Seasonal Influenza
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2012-04-25
- Lead Sponsor
- Novavax
- Target Recruit Count
- 4560
- Registration Number
- NCT01072799
- Locations
- 🇲🇽
Specialities Hospital, National Medical Centre "Siglo XXI" Mexican Institute for Social Security (IMSS), Mexico City, Mexico
Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults
- Conditions
- Influenza
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Novavax
- Target Recruit Count
- 467
- Registration Number
- NCT01014806
- Locations
- 🇺🇸
Universtity Clinical Research, Pembroke Pines, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Brown University, Providence, Rhode Island, United States
Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)
- Conditions
- Seasonal Influenza
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Novavax
- Target Recruit Count
- 221
- Registration Number
- NCT00903552
- Locations
- 🇺🇸
University Clinical Research, Inc., Pembroke Pines, Florida, United States
🇺🇸SNBL Clinical Pharmacology Center, Baltimore, Maryland, United States
Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults
- Conditions
- Influenza
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Novavax
- Target Recruit Count
- 317
- Registration Number
- NCT00754455
- Locations
- 🇺🇸
University Clinical Research, Pembroke Pines, Florida, United States
🇺🇸The Center for Pharmacuetical Research, Kansas City, Missouri, United States
🇺🇸Omega Medical Research, Warwick, Rhode Island, United States
Safety, Reactogenicity and Immunogenicity of an H5N1 VLP
- Conditions
- Pandemic Influenza
- First Posted Date
- 2007-08-22
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Novavax
- Target Recruit Count
- 230
- Registration Number
- NCT00519389
- Locations
- 🇺🇸
Healthcare Discoveries, Inc., San Antonio, Texas, United States